Low-dose rate prostate brachytherapy is well tolerated in patients with a history of inflammatory bowel disease

International Journal of Radiation Oncology Biology Physics

Volumn 66, Issue 2, 2006, Pages 424-429

  Peters, Christopher A ^a   Cesaretti, Jamie A ^a   Stone, Nelson N ^a   Stock, Richard G ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Brachytherapy; Inflammatory bowel disease; Prostate cancer; Radiotherapy

Indexed keywords

DISEASES; RADIOTHERAPY; TOXICITY; TUMORS;

BRACHYTHERAPY; INFLAMMATORY BOWEL DISEASE; PATIENT POPULATION; PROSTATE CANCER;

PATIENT TREATMENT;

IODINE 125; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN;

ADULT; ANAMNESIS; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CROHN DISEASE; DEATH; DRUG IMPLANT; EARLY CANCER; ENTERITIS; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; KAPLAN MEIER METHOD; MALE; PRIORITY JOURNAL; PROCTITIS; PROSTATE CANCER; RADIATION DOSE; RADIATION INJURY; RADIOISOTOPE THERAPY; RECTUM DISEASE; RETROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICAL ANALYSIS; ULCERATIVE COLITIS;

BRACHYTHERAPY; FOLLOW-UP STUDIES; GASTROINTESTINAL HEMORRHAGE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION INJURIES; RECTUM;

EID: 33748320889     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.05.027     Document Type: Article

References (25)

1. Choi P.M., and Zelig M.P. Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: Implications for carcinogenesis and prevention. Gut 35 (1994) 950-954
2. Willett C.G., Ooi C.J., Zietman A.L., et al. Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasms. Int J Radiat Oncol Biol Phys 46 (2000) 995-998
3. Grann A., and Wallner K. Prostate brachytherapy in patients with inflammatory bowel disease. Int J Radiat Oncol Biol Phys 40 (1998) 135-138
4. Stock R.G., Stone N.N., Wesson M.F., et al. A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys 32 (1995) 219-225
5. Stock R.G., Stone N.N., Cesaretti J.A., et al. Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys 64 (2006) 527-533
6. Snyder K.M., Stock R.G., Hong S.M., et al. Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 50 (2001) 335-341
7. O'Brien P.C. Radiation injury of the rectum. Radiother Oncol 60 (2001) 1-14
8. Hopewell J.W., Calvo W., Jaenke R., et al. Microvasculature and radiation damage. Recent Results Cancer Res 130 (1993) 1-16
9. Herold D.M., Hanlon A.L., and Hanks G.E. Diabetes mellitus: A predictor for late radiation morbidity. Int J Radiat Oncol Biol Phys 43 (1999) 475-479
10. Zelefsky M.J., Cowen D., Fuks Z., et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 85 (1999) 1460-1468
11. Skwarchuk M.W., Jackson A., Zelefsky M.J., et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): Multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys 47 (2000) 103-113
12. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
13. Michalski J.M., Purdy J.A., Winter K., et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys 46 (2000) 391-402
14. Michalski J.M., Winter K., Purdy J.A., et al. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Int J Radiat Oncol Biol Phys 62 (2005) 706-713
15. Michalski J.M., Winter K., and Purdy J.A. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV. Int J Radiat Oncol Biol Phys 58 (2004) 735-742
16. Michalski J.M., Winter K., Purdy J.A., et al. Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II. Int J Radiat Oncol Biol Phys 56 (2003) 192-198
17. Ryu J.K., Winter K., Michalski J.M., et al. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys 54 (2002) 1036-1046
18. Wallner K., Roy J., and Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 32 (1995) 465-471
19. Green S., Stock R.G., and Greenstein A.J. Rectal cancer and inflammatory bowel disease: Natural history and implications for radiation therapy. Int J Radiat Oncol Biol Phys 44 (1999) 835-840
20. Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med 312 (1985) 1465-1472
21. Krook J.E., Mrertel C.G., Gunderson L.L., et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 324 (1991) 709-715
22. Sauer R., Becker H., Hohenberger W., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351 (2004) 1731-1740
23. Song D.Y., Lawrie W.T., Abrams R.A., et al. Acute and late radiotherapy toxicity in patients with inflammatory bowel disease. Int J Radiat Oncol Biol Phys 51 (2001) 455-459
24. Waterman F.M., and Dicker A.P. Probability of late rectal morbidity in 125I prostate brachytherapy. Int J Radiat Oncol Biol Phys 55 (2003) 342-353
25. Stone N.N., and Stock R.G. Complications following permanent prostate brachytherapy. Eur Urol 41 (2002) 427-433